• EI
  • Scopus
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
  • DOAJ
  • EBSCO
  • 北大核心期刊
  • 中国核心学术期刊RCCSE
  • JST China
  • FSTA
  • 中国精品科技期刊
  • 中国农业核心期刊
  • CA
  • WJCI
  • 中国科技核心期刊CSTPCD
  • 中国生物医学SinoMed
中国精品科技期刊2020
张亚硕,阿如娜,马鑫彦,等. 荔枝核提取物干预非酒精性脂肪肝病的网络药理学分析及验证[J]. 食品工业科技,2023,44(18):10−19. doi: 10.13386/j.issn1002-0306.2022100271.
引用本文: 张亚硕,阿如娜,马鑫彦,等. 荔枝核提取物干预非酒精性脂肪肝病的网络药理学分析及验证[J]. 食品工业科技,2023,44(18):10−19. doi: 10.13386/j.issn1002-0306.2022100271.
ZHANG Yashuo, A Runa, MA Xinyan, et al. Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease[J]. Science and Technology of Food Industry, 2023, 44(18): 10−19. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022100271.
Citation: ZHANG Yashuo, A Runa, MA Xinyan, et al. Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease[J]. Science and Technology of Food Industry, 2023, 44(18): 10−19. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022100271.

荔枝核提取物干预非酒精性脂肪肝病的网络药理学分析及验证

Network Pharmacological Analyze and Experimental Verification of Lychee Kernel Extract Intervene of Non-alcoholic Fatty Liver Disease

  • 摘要: 目的:运用网络药理学的方法,研究荔枝核提取物(Lychee kernel extract,LKE)干预非酒精性脂肪性肝病(Nonalcoholic fatty liver disease,NAFLD)的作用及分析潜在机制。方法:通过中药系统药理学数据库和分析平台(TCMSP)获取荔枝核的成分和作用靶点,通过疾病靶点数据Genecard获取NAFLD的疾病靶点,然后取交集,通过Cytoscape获取通路-靶点互作网络图,利用微生信网站进行 GO生物过程分析和 KEGG 通路富集分析。建立饮食诱导的肥胖(diet-induced obsisity,DIO)小鼠NAFLD动物模型并用LKE灌胃给药。HE染色观察肝脏脂质变化;试剂盒检测TG、TC、ALT、AST含量。结果:获得荔枝核潜在活性成分18个,与NAFLD疾病交集靶点52个,关键靶点为INS、TNF、HSP90AA1,通过KEGG通路富集筛选得到信号通路20条,主要为癌症通路(pathways in cancer)、动脉粥样硬化通路(Fluid shear stress and atherosclerosis)、糖尿病并发症的信号通路(AGE-RAGE signaling pathway in diabetic complications);模型组小鼠肝脏病变严重,给药组小鼠肝脏病变相对于模型组明显减轻,给药组小鼠血清转氨酶也明显降低,接近正常组,给药组血脂代谢也趋于正常组,且差异均具有显著性(P<0.05)。结论:荔枝核可能通过作用于INS、TNF、HSP90AA1等靶点,调节脂质和动脉粥样硬化通路等起到治疗NAFLD的作用。

     

    Abstract: Objective: To investigate the effect and potential mechanism of lychee kernel extract in the intervention of non-alcoholic fatty liver disease (Nonalcoholic fatty liver disease, NAFLD) based on network pharmacology. Methods: The components and action targets of litchi nuclei were obtained from the Pharmacology Database and Analysis Platform (TCMSP) within the Chinese Medicine System, the disease targets of NAFLD were obtained using disease target data from GeneCard, the intersection and pathway-target interaction network diagram were obtained through Cytoscape, and the GO bioprocess analysis and KEGG pathway enrichment analysis were performed using Bioinformatics website. This study established an animal model with diet-induced obsisity mouse NAFLD and administered LKE via the gastric route. HE staining indicated lipid changes in the liver. The biological kits detect content of TG, TC, ALT, and AST. Results: Eighteen potential active ingredients of litchi nuclei were identified, and 52 targets intersected with NAFLD disease. The key targets were INS, TNF, and HSP90AA1. KEGG channel enrichment filtered 20 signal pathways, the main ones include: Pathways in cancer, fluid shear stress and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications. The liver lesions of the mice in the model group were severe, the liver lesions of the mice in the drug group were significantly reduced compared with the model group, and the serum transaminases of the mice in the drug group were also significantly reduced, which was close to the normal group, and the blood lipid metabolism of the drug group also tended to be normal group,and the differences were significant (P<0.05). Conclusion: Litchi nuclei might play a role in the treatment of NAFLD by acting on such targets as INS, TNF and HSP90AA1, and modulate lipid and atherosclerotic pathways.

     

/

返回文章
返回